VSIG4 and neoplasm: Subsequently, we validated the above analysis through animal experiments by utilizing vivo‐optimized siRNA targeting the VSIG4 gene combined with anti‐PD‐1 monoclonal antibody (anti‐PD‐1 mAb) to treat MC38 tumour‐bearing mice (Figure 7C).